Oral administration of therapeutic peptides is hindered by poor absorption across the gastrointestinal barrier and extensive degradation by proteolytic enzymes. Due to the inherent physicochemical properties of peptides (high molecular weight, enzymatically labile, hydrophilicity, and low permeability), attempts to deliver peptides via the oral route have been broadly unsuccessful. Recently, an oral tablet form of semaglutide (a GLP-1 receptor agonist) was approved by the FDA, EMA, and PMDA for the treatment of type 2 diabetes. Drug absorption in this formulation is contingent upon a dosing regimen with certain food and liquid intake requirements. The Seeker is interested in a potential new oral formulation with no or minimum dosing restrictions related to food and liquid.

Does this sound like you? Click the link below to find out more!